Review ArticleReview
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu and Peng Yuan
Cancer Biology & Medicine August 2021, 18 (3) 849-859; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0463
Nanlin Hu
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Yiran Si
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Jian Yue
2Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Tingting Sun
3Nanjing Geneseeq Technology Inc., Nanjing 210032, China
Xue Wang
2Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Zhuqing Jia
4Cancer Hospital of Huanxing Chaoyang District Beijing, Beijing 100021, China
Songlin Gao
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Qiao Li
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Yang Shao
3Nanjing Geneseeq Technology Inc., Nanjing 210032, China
Jiayu Wang
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Yang Luo
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Fei Ma
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Binghe Xu
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Peng Yuan
2Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
References
- 1.↵
- 2.↵
- Mayer EL,
- Burstein HJ.
- 3.
- 4.↵
- Mariotto AB,
- Etzioni R,
- Hurlbert M,
- Penberthy L,
- Mayer M.
- 5.↵
- 6.↵
- 7.↵Network NCC. NCCN clinical practice guidelines in Oncology (NCCN Guidelines®) Breast Cancer Version 3 2019.
- 8.↵
- Folkman J.
- 9.↵
- 10.↵
- Miles D,
- Cameron D,
- Bondarenko I,
- Manzyuk L,
- Alcedo JC,
- Lopez RI, et al.
- 11.
- Miller K,
- Wang M,
- Gralow J,
- Dickler M,
- Cobleigh M,
- Perez EA, et al.
- 12.
- Robert NJ,
- Dieras V,
- Glaspy J,
- Brufsky AM,
- Bondarenko I,
- Lipatov ON, et al.
- 13.↵
- Brufsky AM,
- Hurvitz S,
- Perez E,
- Swamy R,
- Valero V,
- O’Neill V, et al.
- 14.↵
- 15.↵
- Moreno-Aspitia A,
- Morton RF,
- Hillman DW,
- Lingle WL,
- Rowland KM,
- Jr. ,
- Wiesenfeld M, et al.
- 16.↵
- Burstein HJ,
- Elias AD,
- Rugo HS,
- Cobleigh MA,
- Wolff AC,
- Eisenberg PD, et al.
- 17.↵
- 18.↵
- 19.↵
- Sun Y,
- Niu W,
- Du F,
- Du C,
- Li S,
- Wang J, et al.
- 20.↵
- 21.↵
- Taurin S,
- Yang CH,
- Reyes M,
- Cho S,
- Coombs DM,
- Jarboe EA, et al.
- 22.↵
- Han B,
- Li K,
- Wang Q,
- Zhang L,
- Shi J,
- Wang Z, et al.
- 23.↵
- Chi Y,
- Fang Z,
- Hong X,
- Yao Y,
- Sun P,
- Wang G, et al.
- 24.↵
- 25.↵
- Yang Z,
- Yang N,
- Ou Q,
- Xiang Y,
- Jiang T,
- Wu X, et al.
- 26.↵
- Simon R.
- 27.↵
- 28.↵
- 29.↵
- 30.↵
- Wang G,
- Sun M,
- Jiang Y,
- Zhang T,
- Sun W,
- Wang H, et al.
- 31.↵
- Cobleigh MA,
- Langmuir VK,
- Sledge GW,
- Miller KD,
- Haney L,
- Novotny WF, et al.
- 32.↵
- Kim JY,
- Park K,
- Jung HH,
- Lee E,
- Cho EY,
- Lee KH, et al.
- 33.
- Meric-Bernstam F,
- Zheng X,
- Shariati M,
- Damodaran S,
- Wathoo C,
- Brusco L, et al.
- 34.
- 35.↵
- Cristofanilli M,
- DeMichele A,
- Giorgetti C,
- Turner NC,
- Slamon DJ,
- Im SA, et al.
- 36.↵
- Gawronski AR,
- Lin YY,
- McConeghy B,
- LeBihan S,
- Asghari H,
- Kockan C, et al.
- 37.↵
- Rossi G,
- Mu Z,
- Rademaker AW,
- Austin LK,
- Strickland KS,
- Costa RLB, et al.
In this issue
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu, Peng Yuan
Cancer Biology & Medicine Aug 2021, 18 (3) 849-859; DOI: 10.20892/j.issn.2095-3941.2020.0463
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu, Peng Yuan
Cancer Biology & Medicine Aug 2021, 18 (3) 849-859; DOI: 10.20892/j.issn.2095-3941.2020.0463
Jump to section
Related Articles
- No related articles found.